168 related articles for article (PubMed ID: 22680925)
1. Cellular therapy for ovarian cancer: experimental and clinical perspectives.
Ingersoll SB; Ahmad S; Finkler NJ; Edwards JR; Holloway RW
Curr Med Chem; 2012; 19(22):3787-93. PubMed ID: 22680925
[TBL] [Abstract][Full Text] [Related]
2. Cellular therapy in combination with cytokines improves survival in a xenograft mouse model of ovarian cancer.
Ingersoll SB; Ahmad S; McGann HC; Banks RK; Stavitzski NM; Srivastava M; Ali G; Finkler NJ; Edwards JR; Holloway RW
Mol Cell Biochem; 2015 Sep; 407(1-2):281-7. PubMed ID: 26048718
[TBL] [Abstract][Full Text] [Related]
3. Ovarian cancer biology and immunotherapy.
Latha TS; Panati K; Gowd DS; Reddy MC; Lomada D
Int Rev Immunol; 2014 Oct; 33(5):428-40. PubMed ID: 24911597
[TBL] [Abstract][Full Text] [Related]
4. Past, present and future targets for immunotherapy in ovarian cancer.
Schwab CL; English DP; Roque DM; Pasternak M; Santin AD
Immunotherapy; 2014; 6(12):1279-93. PubMed ID: 25524384
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for ovarian cancer: recent advances and perspectives.
Zsiros E; Tanyi J; Balint K; Kandalaft LE
Curr Opin Oncol; 2014 Sep; 26(5):492-500. PubMed ID: 25036883
[TBL] [Abstract][Full Text] [Related]
6. The Role of the Immune System in Ovarian Cancer and Implications on Therapy.
Menderes G; Schwab CL; Black J; Santin AD
Expert Rev Clin Immunol; 2016 Jun; 12(6):681-95. PubMed ID: 26821930
[TBL] [Abstract][Full Text] [Related]
7. Prospects of chimeric antigen receptor T cell therapy in ovarian cancer.
Jindal V; Arora E; Gupta S; Lal A; Masab M; Potdar R
Med Oncol; 2018 Apr; 35(5):70. PubMed ID: 29651744
[TBL] [Abstract][Full Text] [Related]
8. Anti-ovarian tumor response of donor peripheral blood mononuclear cells is due to infiltrating cytotoxic NK cells.
Pandey V; Oyer JL; Igarashi RY; Gitto SB; Copik AJ; Altomare DA
Oncotarget; 2016 Feb; 7(6):7318-28. PubMed ID: 26802025
[TBL] [Abstract][Full Text] [Related]
9. The development of a novel immunotherapy model of human ovarian cancer in human PBL-severe combined immunodeficient (SCID) mice.
Walker W; Gallagher G
Clin Exp Immunol; 1995 Sep; 101(3):494-501. PubMed ID: 7664496
[TBL] [Abstract][Full Text] [Related]
10. Synergistic cytotoxicity of interferonalpha-2b and interleukin-2 in combination with PBMC against ovarian cancer: development of an experimental model for cellular therapy.
Ingersoll SB; Patel S; Caballero L; Ahmad S; Edwards D; Holloway RW; Edwards JR
Gynecol Oncol; 2009 Jan; 112(1):192-8. PubMed ID: 18995891
[TBL] [Abstract][Full Text] [Related]
11. Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target.
Perales-Puchalt A; Svoronos N; Rutkowski MR; Allegrezza MJ; Tesone AJ; Payne KK; Wickramasinghe J; Nguyen JM; O'Brien SW; Gumireddy K; Huang Q; Cadungog MG; Connolly DC; Tchou J; Curiel TJ; Conejo-Garcia JR
Clin Cancer Res; 2017 Jan; 23(2):441-453. PubMed ID: 27435394
[TBL] [Abstract][Full Text] [Related]
12. Activation of cellular immunity after intracavitary monoclonal antibody therapy of ovarian cancer.
Kosmas C; Epenetos AA; Courtenay-Luck NS
Cancer; 1994 Jun; 73(12):3000-10. PubMed ID: 8199996
[TBL] [Abstract][Full Text] [Related]
13. Emerging immunotherapies in ovarian cancer.
Ojalvo LS; Nichols PE; Jelovac D; Emens LA
Discov Med; 2015 Sep; 20(109):97-109. PubMed ID: 26463091
[TBL] [Abstract][Full Text] [Related]
14. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody.
Canevari S; Stoter G; Arienti F; Bolis G; Colnaghi MI; Di Re EM; Eggermont AM; Goey SH; Gratama JW; Lamers CH
J Natl Cancer Inst; 1995 Oct; 87(19):1463-9. PubMed ID: 7674333
[TBL] [Abstract][Full Text] [Related]
15. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy.
Han X; Wilbanks GD; Devaja O; Ruperelia V; Raju KS
Gynecol Oncol; 1999 Nov; 75(2):198-210. PubMed ID: 10525372
[TBL] [Abstract][Full Text] [Related]
16. Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer.
Sprooten J; Vankerckhoven A; Vanmeerbeek I; Borras DM; Berckmans Y; Wouters R; Laureano RS; Baert T; Boon L; Landolfo C; Testa AC; Fischerova D; Van Holsbeke C; Bourne T; Chiappa V; Froyman W; Schols D; Agostinis P; Timmerman D; Tejpar S; Vergote I; Coosemans A; Garg AD
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795003
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy.
Lo CS; Sanii S; Kroeger DR; Milne K; Talhouk A; Chiu DS; Rahimi K; Shaw PA; Clarke BA; Nelson BH
Clin Cancer Res; 2017 Feb; 23(4):925-934. PubMed ID: 27601594
[No Abstract] [Full Text] [Related]
18. P53-specific T cell responses in patients with malignant and benign ovarian tumors: implications for p53 based immunotherapy.
Lambeck A; Leffers N; Hoogeboom BN; Sluiter W; Hamming I; Klip H; ten Hoor K; Esajas M; van Oven M; Drijfhout JW; Platteel I; Offringa R; Hollema H; Melief K; van der Burg S; van der Zee A; Daemen T; Nijman H
Int J Cancer; 2007 Aug; 121(3):606-14. PubMed ID: 17415711
[TBL] [Abstract][Full Text] [Related]
19. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
20. Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence.
Wefers C; Lambert LJ; Torensma R; Hato SV
Gynecol Oncol; 2015 May; 137(2):335-42. PubMed ID: 25727651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
